Pensioenfonds Rail & OV Purchases Shares of 153,798 Cencora, Inc. (NYSE:COR)

Pensioenfonds Rail & OV acquired a new stake in Cencora, Inc. (NYSE:COR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 153,798 shares of the company’s stock, valued at approximately $37,371,000. Cencora makes up 2.7% of Pensioenfonds Rail & OV’s portfolio, making the stock its 21st largest position.

Other large investors have also made changes to their positions in the company. Rise Advisors LLC purchased a new stake in Cencora during the first quarter worth $25,000. CVA Family Office LLC purchased a new stake in shares of Cencora during the 1st quarter valued at $34,000. Bruce G. Allen Investments LLC purchased a new stake in shares of Cencora during the 1st quarter valued at $43,000. Trust Co. of Vermont purchased a new stake in shares of Cencora during the 4th quarter valued at $62,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of Cencora during the 1st quarter valued at $75,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares in the company, valued at $5,739,017.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,956,675 shares of company stock worth $422,352,056. Insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of several analyst reports. Robert W. Baird increased their price objective on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $233.90.

Cencora Stock Performance

COR traded down $1.05 during midday trading on Wednesday, hitting $237.28. 851,715 shares of the company were exchanged, compared to its average volume of 1,369,290. The company’s 50 day simple moving average is $229.61 and its 200 day simple moving average is $227.60. The firm has a market capitalization of $47.33 billion, a price-to-earnings ratio of 25.99, a price-to-earnings-growth ratio of 1.66 and a beta of 0.48. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $246.75.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. During the same period last year, the firm earned $3.50 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, sell-side analysts predict that Cencora, Inc. will post 13.44 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.